Recent Advances in Treating Endometrial and Cervical Cancers - Episode 16

Emerging Data on Anti-HER2 ADCs in Patients With Cervical Cancer

January 10, 2024

Bradley Monk, MD, Dana M. Chase, MD, FACOG, David O'Malley, MD, Leslie M. Randall, MD, Thomas C. Krivak, MD

Bradley Monk, MD, shares the promising potential of anti-HER2 therapy in cervical cancer and discusses encouraging results from recent trials, emphasizing the importance of testing for HER2 and considering anti-HER2 antibody drug conjugates as a treatment option.

EP. 1: Diagnosing and Staging Patients With Endometrial Cancer

EP. 2: Updated NCCN Guidelines for the Treatment of Advanced or Recurrent Endometrial Cancer

EP. 3: Shared Decision-Making in Advanced or Recurrent Endometrial Cancer

EP. 4: The Role of dMMR in the Progression of Endometrial Cancer

EP. 5: Dostarlimab Plus Carboplatin and Paclitaxel for Advanced or Recurrent Endometrial Cancer: Data from the RUBY Trial

EP. 6: The NRG-GY018 Trial: Pembrolizumab Plus Chemotherapy in Advanced Endometrial Cancer

EP. 7: Emerging Data on Combination Therapies in Advanced or Recurrent Endometrial Cancer

EP. 8: Advances in Anti-HER2 ADCs in Patients With Advanced or Recurrent Endometrial Cancer

EP. 9: Recent Data on Anti-TROP2 ADCs for Patients With Advanced or Recurrent Endometrial Cancer

EP. 10: Future Directions in the Treatment of Advanced or Recurrent Endometrial Cancer

EP. 11: Staging and Biomarker Testing For Patients With Cervical Cancer

EP. 12: Recent Updates in NCCN Guidelines for the Treatment of Recurrent or Metastatic Cervical Cancer